Edward Tenthoff

Yi Chen

Michael Petusky

Yale Jen

James Stamos

Maurice Raycroft

Destiny Buch

- OPKO Health completed the sale of BioReference Health's oncology division, receiving **$192.5 million** at closing and an additional **$32.5 million** in a performance-based earnout, aiming to streamline its lab business.  **[0000944809_2212822_1]** 
- The company reported a Q3 2025 consolidated operating income of **$48.1 million** and net income of **$21.6 million**, or **$0.03 per basic and diluted share**.  **[0000944809_2212822_7]** 
- OPKO Health announced a research collaboration and license agreement with Regeneron, potentially yielding over **$1 billion** in milestone payments and tiered royalties for the development of multi-specific antibodies.  **[0000944809_2212822_1]** **[0000944809_2212822_3]** 
- The company repurchased **11.1 million shares** during Q3 2025, with **$126 million** remaining under its share repurchase program as of September 30.  **[0000944809_2212822_1]** **[0000944809_2212822_6]** 
- For Q4 2025, OPKO Health expects total revenue between **$135 million and $140 million** and anticipates achieving break-even operating results.  **[0000944809_2212822_6]** **[0000944809_2212822_7]**

OPKO Health Reports Q3 2025 Results, Completes Oncology Division Sale, and Announces Regeneron Collaboration

- OPKO Health, Inc. reported **Q3 2025 consolidated total revenues of $151.7 million** and **net income of $21.6 million**, or **$0.03 per diluted share**, which included a **$101.6 million** gain from the sale of BioReference oncology assets.  **[944809_0001193125-25-256325_opk-ex99_1.htm:3]** 
- The company entered a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies, with potential milestone payments exceeding **$200 million** for each program and an overall collaboration value potentially exceeding **$1 billion**.  **[944809_0001193125-25-256325_opk-ex99_1.htm:1]** 
- OPKO completed the sale of BioReference Health's oncology and related clinical assets to Labcorp for **$225 million**, with **$192.5 million** paid at closing, and has repurchased approximately **$73.8 million** of common stock under its program, with **$126.2 million** remaining authorized.  **[944809_0001193125-25-256325_opk-ex99_1.htm:1]** **[944809_0001193125-25-256325_opk-ex99_1.htm:3]** 
- The FDA approved a supplemental application for the **4Kscore® Test** in July 2025, enabling its performance without digital rectal examination information.  **[944809_0001193125-25-256325_opk-ex99_1.htm:2]**

OPKO Health Reports Q3 2025 Financial Results and Strategic Business Highlights

- OPKO Health reported **total revenues of $151.7 million** for the third quarter of 2025, compared to **$173.6 million** for the same period in 2024, with **net income of $21.6 million** or **$0.03 per diluted share**.  **[944809_ac2752fa87654976b8eb923a35e4650a_3]** 
- The company completed the **sale of BioReference Health's oncology and related clinical assets to Labcorp for $225 million**, receiving **$192.5 million** at closing, and intends to utilize a portion of the proceeds for its **share repurchase program**.  **[944809_ac2752fa87654976b8eb923a35e4650a_0]** 
- OPKO entered into a **research collaboration with Regeneron Pharmaceuticals** to develop multispecific antibodies, with potential milestone payments that could **exceed $1 billion** if multiple products are successful.  **[944809_ac2752fa87654976b8eb923a35e4650a_0]** 
- The FDA approved a supplemental application for the **4Kscore® Test**, allowing its performance without digital rectal examination information.  **[944809_ac2752fa87654976b8eb923a35e4650a_2]**

OPKO Health Reports Q3 2025 Financial Results, Announces Regeneron Collaboration and Asset Sale

- **ModeX Therapeutics**, an OPKO Health company, has entered a license and collaboration agreement with **Regeneron Pharmaceuticals Inc.** to discover and develop multispecific antibodies for several therapeutic indications.  **[944809_2d33403af756433eb596a3cb9239cf07_1]** 
- Under the terms of the agreement, ModeX will receive an **upfront payment of $7 million**.  **[944809_2d33403af756433eb596a3cb9239cf07_1]** 
- The collaboration has a potential total value exceeding **$1 billion** if multiple products are successful, with potential future payments exceeding **$200 million per selected molecule** and tiered global net sales royalties up to low double digits.  **[944809_2d33403af756433eb596a3cb9239cf07_0]** **[944809_2d33403af756433eb596a3cb9239cf07_1]** 
- Regeneron will fund and lead all preclinical, clinical development, and commercialization activities for any products it elects to advance.  **[944809_2d33403af756433eb596a3cb9239cf07_1]**

OPKO Health's ModeX Therapeutics Announces Collaboration with Regeneron

- On **September 15, 2025**, OPKO Health, Inc. completed the sale of select oncology and oncology-related clinical testing services businesses of its subsidiary, BioReference Health, to Labcorp.  **[944809_0001193125-25-203530_opk-20250915.htm:0]** **[944809_0001193125-25-203530_opk-ex99_1.htm:0]** **[944809_0001193125-25-203530_opk-20250915.htm:1]** 
- The total purchase price for the transaction is up to **$225 million**, including **$192.5 million** paid at closing and up to **$32.5 million** in a contingent earnout based on performance.  **[944809_0001193125-25-203530_opk-ex99_1.htm:0]** **[944809_0001193125-25-203530_opk-20250915.htm:1]** 
- BioReference Health will retain its core clinical testing operations in the New York and New Jersey region and its **4Kscore® Test franchise**, which generated approximately **$300 million in revenue for 2024**.  **[944809_0001193125-25-203530_opk-ex99_1.htm:0]** 
- OPKO intends to utilize a portion of the proceeds from the sale to fund its **recently expanded share repurchase authorization**.  **[944809_0001193125-25-203530_opk-ex99_1.htm:0]**

OPKO Health Completes Sale of BioReference Health's Oncology and Clinical Testing Businesses to Labcorp

- Entera Bio, in collaboration with OPKO Health, presented positive preclinical pharmacokinetic data for their oral GLP-2 analog, OPK-8801003, for Short Bowel Syndrome (SBS) at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress on **September 15, 2025**.  **[944809_c3c40d73b5f84d5082b10717bceb8b74_0]** 
- The OPK-8801003 GLP-2 tablet demonstrated an **extended half-life of approximately 15 hours** in minipigs, an 18-fold improvement over teduglutide, and robust oral bioavailability with peak plasma concentrations reaching ~**200 ng/ml** (Cmax).  **[944809_c3c40d73b5f84d5082b10717bceb8b74_0]** 
- This oral tablet candidate aims to provide a less-invasive administration for the approximately **30,000 SBS patients** who currently rely on daily injections of Gattex®, which generates approximately **$800 million** in annual sales.  **[944809_c3c40d73b5f84d5082b10717bceb8b74_0]** **[944809_c3c40d73b5f84d5082b10717bceb8b74_1]**

OPKO HEALTH (OPK)